Pterodontic acid for COVID-19
COVID-19 involves the interplay of over 100 viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed over 9,000 potential treatments.
c19early.org analyzes
160+ treatments.
, Identification of putative antiviral bioactive compounds derived from family Asteraceae: An in silico approach, Journal of Cellular Biochemistry, doi:10.1002/jcb.30538
AbstractThis computational study investigates 21 bioactive compounds from the Asteraceae family as potential inhibitors targeting the Spike protein (S protein) of SARS‐CoV‐2. Employing in silico methods and simulations, particularly CDOCKER and MM‐GBSA, the study identifies two standout compounds, pterodontic acid and cichoric acid, demonstrating robust binding affinities (−46.1973 and −39.4265 kcal/mol) against the S protein. Comparative analysis with Favipiravir underscores their potential as promising inhibitors. Remarkably, these bioactives exhibit favorable ADMET properties, suggesting safety and efficacy. Molecular dynamics simulations validate their stability and interactions, signifying their potential as effective SARS‐CoV‐2 inhibitors.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.